The influence of the hematological complications on the efficiency of the systemic therapy of breast cancer

The interest in studying the effect of haematological complications on survival of patients with solid tumors during chemotherapy has increased in recent years. The results of various global studies are ambiguous and often opposite. The objectives of our study was to investigate the dynamics of hem...

Full description

Bibliographic Details
Main Author: Prokhach A.V.
Format: electronic Article
Language:English
Russian
Ukrainian
Physical Description:Online-Ressource
QR Code: Show QR Code
LEADER 02267nma a2200265 c 4500
001 DOAJ016714342
003 DE-601
005 20191108074954.0
007 cr uuu---uuuuu
008 171226s2016 000 0 eng d
035 |a (DE-599)DOAJ817184d6734d414d82fcdceaa4fc8342 
040 |b ger  |c GBVCP 
041 0 |a eng  |a rus  |a ukr 
100 0 |a Prokhach A.V. 
245 1 4 |a The influence of the hematological complications on the efficiency of the systemic therapy of breast cancer  |h Elektronische Ressource 
300 |a Online-Ressource 
520 |a The interest in studying the effect of haematological complications on survival of patients with solid tumors during chemotherapy has increased in recent years. The results of various global studies are ambiguous and often opposite. The objectives of our study was to investigate the dynamics of hematological parameters during the course of chemotherapy, their impact on health outcomes and indicators of survival of patients. Retrospectively, medical records of 110 patients with inoperable breast cancer, who received palliative chemotherapy courses by the scheme taxanes + anthracyclines, were analyzed. Dynamics of neutrophils indicators, hemoglobin, platelets, tumor response according to RECIST criteria of 1.1., as well as the long-term outcomes were studied. It was found that the most intensively level of hemoglobin reduced at the first cycle of treatment (81.1% of patients), later it stabilized (17.7-37.3%) (p<0.05). During the first treatment cycle neutropenia occurs in 71.1-78.2% of patients, thrombocytopenia – in 3.6-5.55%. Later, thrombocytopenia rate reduced to 1.2-1.9%, neutropenia – to 58.3-63.5% (p<0.05). The presence of neutropenia causes significantly positive impact on the results of treatment of patients with metastatic breast cancer. In the presence of neutropenia during chemotherapy, indicators of general and disease-free survival are reliably higher. 
773 0 8 |i In  |g  (01.05.2016) 
856 4 0 |y DOAJ  |u https://doaj.org/article/817184d6734d414d82fcdceaa4fc8342 
856 4 0 |u http://medpers.dsma.dp.ua/issues/2016/N2/74-77.pdf 
856 4 0 |u https://doaj.org/toc/2307-0404 
856 4 0 |u https://doaj.org/toc/2307-0404 
912 |a GBV_DOAJ 
951 |a AR 
952 |j 2016  |b 01  |c 05